{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:02:33Z","timestamp":1740106953518,"version":"3.37.3"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00277-022-04956-y","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T16:08:19Z","timestamp":1660752499000},"page":"2563-2564","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Review of the risk of thrombosis or bleeding upon abrupt anagrelide discontinuation in patients with essential thrombocythemia"],"prefix":"10.1007","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8293-5779","authenticated-orcid":false,"given":"Marta","family":"Santaliestra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisca","family":"Ferrer-Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Alvarez-Larr\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"On Behalf of the MPN Spanish Group (GEMFIN)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"issue":"Suppl","key":"4956_CR1","doi-asserted-by":"publisher","first-page":"S114","DOI":"10.1016\/j.clml.2016.02.029","volume":"16","author":"C Besses","year":"2016","unstructured":"Besses C, Alvarez-Larr\u00e1n A (2016) How to treat essential thrombocythemia and polycythemia vera. Clin Lymphoma Myeloma Leuk 16(Suppl):S114\u2013S123. https:\/\/doi.org\/10.1016\/j.clml.2016.02.029","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4956_CR2","unstructured":"European Medicines Agency (EMA) (2009) Xagrid (anagrelide). An overview of Xagrid and why it is authorised in the EU.\u00a0Retrieved 15 May 2022, from\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/overview\/xagrid-epar-medicine-overview_en.pdf"},{"issue":"11","key":"4956_CR3","first-page":"1306","volume":"89","author":"MG Mazzucconi","year":"2004","unstructured":"Mazzucconi MG, Redi R, Bernasconi S, Bizzoni L, Dragoni F, Latagliata R, Santoro C, Mandelli F (2004) A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica 89(11):1306\u20131313","journal-title":"Haematologica"},{"key":"4956_CR4","doi-asserted-by":"publisher","unstructured":"Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; ANAHYDRET Study Group (2013) Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 121(10):1720\u20131728. https:\/\/doi.org\/10.1182\/blood-2012-07-443770","DOI":"10.1182\/blood-2012-07-443770"},{"key":"4956_CR5","unstructured":"European Medicines Agency (EMA) (2022) Xagrid (anagrelide hydrochloride): Risk of thrombosis including cerebral infarction upon abrupt treatment discontinuation.\u00a0Retrieved 15 May 2022, from\u00a0https:\/\/www.ema.europa.eu\/en\/medicines\/dhpc\/xagrid-anagrelide-hydrochloride-risk-thrombosis-including-cerebral-infarction-upon-abrupt-treatment"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04956-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04956-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04956-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T05:03:09Z","timestamp":1665118989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04956-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":5,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["4956"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04956-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2022,8,17]]},"assertion":[{"value":"25 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}